Zolpidem modified-release in insomnia

Zolpidem modified-release (MR) is the first hypnotic agent to be marketed in an extended-release formulation. Zolpidem MR is a two-layered, biphasic release tablet indicated for the management of induction of sleep and sleep maintenance. The pharmacokinetics of the drug are similar to those of immed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirkwood, Cynthia, Neill, Jason, Breden, Ericka
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656288/
https://www.ncbi.nlm.nih.gov/pubmed/19300582
_version_ 1782165487640117248
author Kirkwood, Cynthia
Neill, Jason
Breden, Ericka
author_facet Kirkwood, Cynthia
Neill, Jason
Breden, Ericka
author_sort Kirkwood, Cynthia
collection PubMed
description Zolpidem modified-release (MR) is the first hypnotic agent to be marketed in an extended-release formulation. Zolpidem MR is a two-layered, biphasic release tablet indicated for the management of induction of sleep and sleep maintenance. The pharmacokinetics of the drug are similar to those of immediate-release zolpidem. Two double-blind, placebo-controlled, parallel-group trials demonstrated efficacy in adults and elderly patients treated with zolpidem MR for 3 weeks without significant impairment in next-day psychomotor functioning. The most common adverse effects with zolpidem MR were dizziness, somnolence, and headache. A starting dose of zolpidem MR 12.5 mg is recommended for adults and 6.25 mg for elderly patients.
format Text
id pubmed-2656288
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26562882009-03-19 Zolpidem modified-release in insomnia Kirkwood, Cynthia Neill, Jason Breden, Ericka Neuropsychiatr Dis Treat Expert Opinion Zolpidem modified-release (MR) is the first hypnotic agent to be marketed in an extended-release formulation. Zolpidem MR is a two-layered, biphasic release tablet indicated for the management of induction of sleep and sleep maintenance. The pharmacokinetics of the drug are similar to those of immediate-release zolpidem. Two double-blind, placebo-controlled, parallel-group trials demonstrated efficacy in adults and elderly patients treated with zolpidem MR for 3 weeks without significant impairment in next-day psychomotor functioning. The most common adverse effects with zolpidem MR were dizziness, somnolence, and headache. A starting dose of zolpidem MR 12.5 mg is recommended for adults and 6.25 mg for elderly patients. Dove Medical Press 2007-10 /pmc/articles/PMC2656288/ /pubmed/19300582 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Expert Opinion
Kirkwood, Cynthia
Neill, Jason
Breden, Ericka
Zolpidem modified-release in insomnia
title Zolpidem modified-release in insomnia
title_full Zolpidem modified-release in insomnia
title_fullStr Zolpidem modified-release in insomnia
title_full_unstemmed Zolpidem modified-release in insomnia
title_short Zolpidem modified-release in insomnia
title_sort zolpidem modified-release in insomnia
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656288/
https://www.ncbi.nlm.nih.gov/pubmed/19300582
work_keys_str_mv AT kirkwoodcynthia zolpidemmodifiedreleaseininsomnia
AT neilljason zolpidemmodifiedreleaseininsomnia
AT bredenericka zolpidemmodifiedreleaseininsomnia

Ejemplares similares